Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2W2VmlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh|ryP MVLTRW5ITVJ?
CAL-51 cell NYDQNo1YT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVI3KG6P MnztV2FPT0WU
ABC-1 cell M1nZXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmjCTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y2KG6P Mn75V2FPT0WU
A2780 cell NEnOOIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NILzcnNKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42QTRibl2= MmrHV2FPT0WU
ES1 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4rrRmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? NIizWWlUSU6JRWK=
HUTU-80 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnO5TY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTFibl2= NXXKNGFXW0GQR1XS
NCI-H292 cell MojJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYDwPHdUUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEi2JI5O M3jBPHNCVkeHUh?=
NB69 cell MkTlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlP3TY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6yNkBvVQ>? MUHTRW5ITVJ?
ES8 cell M1;xZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVvRToU6UW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMzKG6P M{DBc3NCVkeHUh?=
BCPAP cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVzJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zOEBvVQ>? NHi4V2ZUSU6JRWK=
T-24 cell NXr1OoM4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1JI5O NW\xNFVJW0GQR1XS
EW-16 cell NXnueG0yT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4rsTmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyKG6P M3f2fnNCVkeHUh?=
OVCAR-5 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnrxTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?= NHT2Wo5USU6JRWK=
SF126 cell NYiwdWFXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn;ITY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVUhdk1? NFK1UmdUSU6JRWK=
KP-4 cell M2P0dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUO4R2lWUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPyCwTR?= NEfXZXFUSU6JRWK=
GAMG cell M2npfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXnJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O NF20b|FUSU6JRWK=
HOS cell NIL4eVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmPTTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWzJI5O MWjTRW5ITVJ?
CHL-1 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEHpV3BKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?= NUfGPGE2W0GQR1XS
AGS cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkDKTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lki2JI5O M2TmTHNCVkeHUh?=
MDA-MB-157 cell NFmydXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn;GTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MjDuUS=> MX\TRW5ITVJ?
HSC-3 cell NGi5OZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkfWTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? NEnhWJJUSU6JRWK=
CAL-72 cell NYL2VpV[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3\JR2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?= MlzWV2FPT0WU
NBsusSR cell Mm\mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE{KG6P M3zrPHNCVkeHUh?=
ES7 cell MnTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFfpcldKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVkhdk1? M3;5ZXNCVkeHUh?=
H-EMC-SS cell NX72dlhMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnWyTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2= MXLTRW5ITVJ?
NCI-H1703 cell NI\tT|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGW5[YZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNkigcm0> Mk\mV2FPT0WU
BHT-101 cell NGLJW4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFTUVItKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd{IH7N Ml7wV2FPT0WU
SK-OV-3 cell NWnMUpMzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVrTWY9GUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=> NVfPbWgxW0GQR1XS
EW-24 cell NWftfVNJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoHWTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFMhdk1? MlTDV2FPT0WU
PSN1 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXywW41uUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45PCCwTR?= M3jVZXNCVkeHUh?=
OVCAR-8 cell Ml3oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2TXUWlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2= M2mwdXNCVkeHUh?=
NCI-H1563 cell NELmO|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFn5copKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU3OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMUOgcm0> Mlj5V2FPT0WU
SW756 cell NVnx[ZdCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVvCT4lWUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2= NGryXWpUSU6JRWK=
A375 cell M3;RU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGj3SYNKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE1KG6P MnfMV2FPT0WU
Ca9-22 cell NX3M[nNqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlUhdk1? MWXTRW5ITVJ?
SW1990 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rhS2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzOUmwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{OiCwTR?= M2rRSnNCVkeHUh?=
ES4 cell MoH3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwM{mgcm0> NHzpTYZUSU6JRWK=
HCE-T cell M1Tre2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mlr6TY5pcWKrdHnvckBw\iCqdX3hckBJS0VvVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFUhdk1? Mk\nV2FPT0WU
MOLT-16 cell MlHpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHrLOVVKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV|IH7N NHHRNYdUSU6JRWK=
HSC-4 cell MoHrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND64JI5O NEP5OIdUSU6JRWK=
NCI-SNU-1 cell NHv3fWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NITDd4xKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOE[gcm0> NYLCfWxpW0GQR1XS
EW-11 cell M2H3emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\2O2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlkhdk1? NIi3[ZhUSU6JRWK=
HT-1080 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6KG6P MWrTRW5ITVJ?
MES-SA/Dx5 cells MkK3R5l1d3SxeHnjbZR6KGG|c3H5 NGTkTVREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzMEBKSzVyPUWgcm0> MkfMNlM6Ozd7OEG=
SW1710 cell NEjGOpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NISxbpBKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2= NYfPclhWW0GQR1XS
EW-1 cell NYHLXnlrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGjMOmpKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI1KG6P NFqx[ZFUSU6JRWK=
BV-173 cell M{C2dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHWwd3hKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzlibl2= M1;1dXNCVkeHUh?=
TE-8 cell MnfRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmHNTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60NUBvVQ>? MV\TRW5ITVJ?
G-401 cell NXniUoVrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUnGS4lTUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2= M1LxZnNCVkeHUh?=
KOSC-2 cell MlXHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1nZ[mlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?= M1fqSXNCVkeHUh?=
HuCCT1 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlnOTY5pcWKrdHnvckBw\iCqdX3hckBJfUOFVEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlUzKG6P NH7VU5VUSU6JRWK=
FADU cell M3m2WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3jiTmlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlYhdk1? MYrTRW5ITVJ?
MHH-ES-1 cell MmDtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW\q[YNTUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkmgcm0> NX72e2pPW0GQR1XS
ES3 cell M17xSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV75RlFuUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6KG6P M3ruSHNCVkeHUh?=
OVCAR-4 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE\YW2NKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njh5IH7N NFjLVZRUSU6JRWK=
HD-MY-Z cell NHnpbG9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFrzVmJKdmirYnn0bY9vKG:oIHj1cYFvKEiGLV3ZMXoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjlzIH7N Mn3wV2FPT0WU
human JAR cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIr3bHRKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? NGPyTYhUSU6JRWK=
A427 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O MnHFV2FPT0WU
697 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3CTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkGzJI5O MWjTRW5ITVJ?
OVCAR-3 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYjJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIhdk1? NYfEO|FMW0GQR1XS
human NB14 cell Mlj1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWfYfmRtUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PCCwTR?= NHTv[olUSU6JRWK=
GB-1 cell M{[xfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX;ae4I6UW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?= MkfZV2FPT0WU
COR-L105 cell NF7LfWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44PiCwTR?= MUDTRW5ITVJ?
647-V cell NWXPd2RVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLSWIRrUW6qaXLpeIlwdiCxZjDoeY1idiB4NEetWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQSCwTR?= M132[3NCVkeHUh?=
human K5 cell MnPMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVruSYNiUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUegcm0> NYSwdoFTW0GQR1XS
DMS-273 cell M{fCPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWXHWIdwUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=> NHnTN2pUSU6JRWK=
UM-UC-3 cell MkDES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mle4TY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= Mn;LV2FPT0WU
HEL cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWPpd5dRUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA5KG6P NILPd5FUSU6JRWK=
human KU-19-19 cell NF7IXJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWOwVW5bUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> Mnz2V2FPT0WU
MC-IXC cell NX:2UHdKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkjQTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlE4KG6P MXXTRW5ITVJ?
human H4 cell NXjwSGt3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5{NTDuUS=> NUHjSpBIW0GQR1XS
NUGC-3 cell M2LpS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV;lVFViUW6qaXLpeIlwdiCxZjDoeY1idiCQVVfDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN|IH7N Mo\IV2FPT0WU
CHP-212 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4nONWlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzRibl2= MXHTRW5ITVJ?
human SW982 cell M3\4fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1jZdmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ1KG6P M1jUXXNCVkeHUh?=
C-33-A cell M{DLWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIjQT5ZKdmirYnn0bY9vKG:oIHj1cYFvKENvM{OtRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPThibl2= NV[1R4g6W0GQR1XS
PC-3 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUjaNoplUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?= M{LWTXNCVkeHUh?=
COLO-684 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmPaTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2= NHraW5RUSU6JRWK=
SNU-387 cell NITkR3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWrPZ5NOUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS52OTDuUS=> MWDTRW5ITVJ?
U251 cell NIXVfVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NW\3OlNEUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU45PiCwTR?= MWXTRW5ITVJ?
A673 cell M2\Cd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2fITWlvcGmkaYTpc44hd2ZiaIXtZY4hSTZ5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlYhdk1? MVzTRW5ITVJ?
human T47D cell M{j4PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEizTXNKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44QSCwTR?= MWrTRW5ITVJ?
A549 cell NU\nd|lkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWLtOldWUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPiCwTR?= NH3rWXRUSU6JRWK=
PC-14 cell M1j3RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUDqSnZYUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1Njd|IH7N NXXVWYx3W0GQR1XS
A704 cell MnzaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>? M2DYTHNCVkeHUh?=
MCF7 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|MT6zOkBvVQ>? NYPhbIR1W0GQR1XS
PC3 cells NIDXNY5HfW6ldHnvckBie3OjeR?= NFvWN3pKdmirYnn0bY9vKG:oIGDET|EudWWmaXH0[YQhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhicnXzbYR2\SCrbjDoeY1idiCSQ{OgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC5zMUOg{txO NFnsV2wzOTN2MU[3OS=>
F-36P cells M1\RdHBzd2yrZnXyZZRqd25iYYPzZZk> MmLBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCILUO2VEBk\WyuczygTWM2OD1yLkK4JO69VQ>? MnfiNlE{PDF4N{W=
OCI-AML2 cells MlK5VJJwdGmoZYLheIlwdiCjc4PhfS=> MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN|Uh|ryP NGry[oIzOTN2MU[3OS=>
K562 cells NVqyT5pKWHKxbHnm[ZJifGmxbjDhd5NigQ>? MnvmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|LDDJR|UxRTF6IN88US=> M{XNTFIyOzRzNke1

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID